Unknown

Dataset Information

0

Telomere length predicts for outcome to FCR chemotherapy in CLL.


ABSTRACT: We have previously shown that dividing patients with CLL into those with telomeres inside the fusogenic range (TL-IFR) and outside the fusogenic range (TL-OFR) is powerful prognostic tool. Here, we used a high-throughput version of the assay (HT-STELA) to establish whether telomere length could predict for outcome to fludarabine, cyclophosphamide, rituximab (FCR)-based treatment using samples collected from two concurrent phase II studies, ARCTIC and ADMIRE (n?=?260). In univariate analysis, patients with TL-IFR had reduced progression-free survival (PFS) (P?

SUBMITTER: Norris K 

PROVIDER: S-EPMC6756045 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Telomere length predicts for outcome to FCR chemotherapy in CLL.

Norris Kevin K   Hillmen Peter P   Rawstron Andrew A   Hills Robert R   Baird Duncan M DM   Fegan Christopher D CD   Pepper Chris C  

Leukemia 20190130 8


We have previously shown that dividing patients with CLL into those with telomeres inside the fusogenic range (TL-IFR) and outside the fusogenic range (TL-OFR) is powerful prognostic tool. Here, we used a high-throughput version of the assay (HT-STELA) to establish whether telomere length could predict for outcome to fludarabine, cyclophosphamide, rituximab (FCR)-based treatment using samples collected from two concurrent phase II studies, ARCTIC and ADMIRE (n = 260). In univariate analysis, pat  ...[more]

Similar Datasets

| S-EPMC7808927 | biostudies-literature
| S-EPMC3277142 | biostudies-other
| S-EPMC8053994 | biostudies-literature
| S-EPMC8622208 | biostudies-literature
| S-EPMC8046773 | biostudies-literature
| S-EPMC6276896 | biostudies-other
| S-EPMC5949099 | biostudies-literature
| S-EPMC6887113 | biostudies-literature
| S-EPMC5744955 | biostudies-literature